Promoter holding
64.27%
OB
Onyx Biotec Limited - Due diligence report
A 360° intelligence report on Onyx Biotec Limited: trust score, financial health, credit view, compliance, directors, growth and distress si…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Onyx Biotec Limited — 360° Intelligence Report
Generated from MCA filings & public records87/100
Trust Score
Low Risk
Onyx Biotec Limited is assessed as Low Risk with a Trust Score of 87/100. Onyx Biotec Limited is an active public limited indian non-government company incorporated in 2005, operating in the Chemicals sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 11 Aug 2026 from the latest processed filings. Onyx Biotec Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
87/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
75/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
60/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 60/100 Moderate
- Open charges exceed net worth - secured lenders rank ahead.
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 5 open (32.03 cr) · 19 satisfied (62.97 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Hdfc Bank Limited | 4 | 48.0 cr |
| Axis Bank Limited | 6 | 48.0 cr |
| Others | 5 | 48.0 cr |
| State Bank Of India | 1 | 48.0 cr |
| Aditya Birla Finance Limited | 2 | 48.0 cr |
| Sidbi | 2 | 48.0 cr |
Compliance Score: 75/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- 2 auditor resignation(s) filed - latest: VIVEK SINGLA & ASSOCIATES on 2024-05-01.
- Delayed payments to MSME suppliers disclosed (20 disclosure(s)).
- 1 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| NARESH KUMAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PARMJEET KAUR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HARSH MAHAJAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Nitesh Garg | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Prince Preet Singh | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VINEET SINGH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Harsh Mahajan | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 7 directors on the board.
- No disqualified or deactivated DINs.
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
15 allotment(s) · 0 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Key managerial personnel: NARESH KUMAR (Whole-time director) · HARSH MAHAJAN (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 95 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +38% over 4 year(s).
Latest year revenue grew 1.42.
Profit expanded 2.1x year-on-year.
Asset base grew 24% - capacity expansion.
Net margin improved to 0.86.
EPFO headcount growing - hiring signal.
Operating for 21+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
5 open charge(s) registered - assets are encumbered.
2 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 34.38 Lakh.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence83/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment73/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 5 open charge(s) of 32.03 cr already registered.
- Compliance record supports lending.
Investor view91/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 6 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events04 Jul 2026
Charge satisfied
Others
17 Feb 2026
Charge created
Others - 22.00 Lakh
27 Sep 2025
Last AGM held
Annual general meeting
29 Aug 2025
Charge satisfied
Axis Bank Limited
31 Jul 2025
Charge created
Others - 4.50 cr
31 Mar 2025
Latest balance sheet
Filed with ROC
19 Feb 2025
Charge satisfied
Hdfc Bank Limited
22 Jan 2025
Director ceased
Harsh Jhunjhunwala
21 Jan 2025
Charge created
Hdfc Bank Limited - 29.50 cr
05 Nov 2024
Charge satisfied
Hdfc Bank Limited
08 Aug 2024
Charge satisfied
Others
02 Aug 2024
Charge satisfied
Icici Bank Limited
01 Aug 2024
Director appointed
Harsh Mahajan (Cfo)
31 Jul 2024
Charge satisfied
Axis Bank Limited
26 Jul 2024
Director appointed
Nitesh Garg (Director)
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
7 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 15 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Evolet Pharmaceuticals Private Limited | U24230HR2005PTC127251 | Bhorakalan, Haryana, India |
| Custom Capsules Private Limited | U24235MH1988PTC048924 | Mumbai, Maharashtra, India |
| Thinq | U24239MH2006PLC165473 | Mumbai, Maharashtra, India |
| Oxford Laboratories | U24230MH2000PTC123927 | Mumbai, Maharashtra, India |
| Anmol Chemicals Private Limited | U24290MH2023PTC398046 | Mumbai, Maharashtra, India |
| Unimarck Pharma | U24232CH1984PLC005768 | Chandigarh, Chandigarh, India |
| Delta Biopharma Private Limited | U24100MH2012PTC238604 | Mumbai, Maharashtra, India |
| Vadivel Pyrotechs Private Limited | U36993TN2011PTC079868 | Sivakasi, Tamil Nadu, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Onyx Biotec Limited before audits and certifications: compliance score 75/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Onyx Biotec Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 60/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Onyx Biotec Limited - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 87/100, distress signals and MSME payment-delay disclosures - know whether Onyx Biotec Limited pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Onyx Biotec Limited - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Onyx Biotec Limited an active company?
Onyx Biotec Limited has MCA status “Active” with a compliance score of 75/100 (Low Risk).
Is Onyx Biotec Limited financially healthy?
Onyx Biotec Limited has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.
Should I do business with Onyx Biotec Limited?
Its overall Trust Score is 87/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Onyx Biotec Limited?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 7 active director(s) are on record.
Does Onyx Biotec Limited have loans or charges against its assets?
5 open charge(s) are registered against its assets, and 19 earlier charge(s) stand satisfied.
Is Onyx Biotec Limited up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 75/100 (Low Risk).
Is it risky to lend to Onyx Biotec Limited?
Its Credit Risk Score is 60/100 (Moderate). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
